About CSL Ltd (ASX: CSL)
CSL Limited is a global biopharmaceutical company engaged in the research, development, manufacture, and distribution of biopharmaceutical products and vaccines across Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and a range of other international markets. The company operates through three segments, CSL Behring, CSL Seqirus, and CSL Vifor, each addressing distinct therapeutic needs across a broad patient population.
CSL Behring focuses on plasma products, gene therapies, and recombinants, serving patients with conditions spanning immunology, hematology, cardiovascular and metabolic disease, respiratory conditions, and transplant medicine. CSL Seqirus manufactures and distributes influenza-related products and provides pandemic preparedness services to governments, while CSL Vifor addresses iron deficiency and nephrology through its dedicated product portfolio. The company also licenses its intellectual property as part of its broader commercial operations. Founded in 1916, CSL Limited is headquartered in Melbourne, Australia.
MFAM Research
- [BUY] CSL Ltd (ASX: CSL) Why Tariff Noise Does Not Change the Buy ThesisApril 8, 2026CSL Ltd (ASX:CSL) Why Tariff Noise Does Not Change the Buy Thesis CSL has pulled back meaningfully from its highs, and the latest round of tariff headlines has only added to the pressure. But when we dig into the actual exposure, the picture looks far more manageable than the market seems to be pricing in. […]
Latest Announcements
- CSL (ASX: CSL) – CSL Files FY2026 Results PresentationAugust 18, 2026I need the actual financial results and metrics from the announcement to write this accurately. The text you provided contains only the cover page, contact details, and standard disclaimers—but no revenue figures, earnings, profit, guidance, or other performance data that would form the core of an analyst commentary. To write the 400-500 word piece you’ve […]
- CSL (ASX: CSL) – CSL FY2026 Results Part 5August 18, 2026CSL Limited reported FY2026 results that mask a complex underlying story. While the reported loss of US$2.6 billion appears dramatic, this reflects US$7.1 billion in impairments rather than operational collapse. Underneath, the company achieved underlying NPATA of US$3.1 billion on revenues of US$15.8 billion, with cash generation of US$3.5 billion from operations. Management characterizes FY26 […]
- CSL (ASX: CSL) – CSL Files FY2026 Statutory AccountsAugust 18, 2026CSL Limited has reported a statutory net loss of US$2.579 billion for the financial year ended 30 June 2026, representing a swing of 186% from the prior year’s profit of US$3.219 billion. This dramatic reversal signals significant one-off charges, impairments, or amortisation expenses that substantially outweighed the company’s underlying operational performance. The underlying NPATA, which […]
- CSL (ASX: CSL) – CSL Enhanced Plasma Manufacturing UpdateJuly 29, 2026CSL Limited has announced plans to launch clinical trials evaluating its next generation Horizon 2 manufacturing process for immunoglobulin production. The company’s move signals progress toward regulatory approval of a technology that could meaningfully enhance operational efficiency and production capacity across its plasma-based business, a key driver of profitability in the coming years. Horizon 2 […]
- CSL (ASX: CSL) – Interim CEO 90 Day Review and Financial UpdateMay 11, 2026CSL Limited has downgraded its FY26 financial guidance following interim Chief Executive Gordon Naylor’s 90-day review of the company, revising expected revenue to around $15.2 billion and NPATA (excluding restructuring costs and impairments) to approximately $3.1 billion, both on a constant currency basis. This represents a material reduction from previous expectations and signals that benefits […]
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Biotechnology |
|---|---|